Immunovaccine Announces Changes to Stock Option Plan
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwired) -- 10/06/14 -- Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that its board of directors has approved a modification to the Company''s stock option plan (the "Plan"). Under this amendment, the Company will increase the number of common shares of the Company reserved for issuance under the Plan from 6,750,000 to 9,100,000. The amendment to the Plan is pending approval by the TSX Venture Exchange.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company''s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.
Connect at
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Dr. Marc Mansour
Chief Executive Officer
Immunovaccine Inc.
(902) 492-1819
Tim Brons
Vida Strategic Partners (media)
(415) 675-7402
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2014 - 06:00 Uhr
Sprache: Deutsch
News-ID 1307491
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 105 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunovaccine Announces Changes to Stock Option Plan
"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunovaccine Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
